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MicroCTMethods currently used to analyse osteolytic lesions caused by malignancies such as multiple myeloma and
metastatic breast cancer vary from basic 2-D X-ray analysis to 2-D images of micro-CT datasets analysed with
non-specialised image software such as ImageJ. However, these methods have signiﬁcant limitations. They do
not capture 3-D data, they are time-consuming and they often suffer from inter-user variability. We therefore
sought to develop a rapid and reproducible method to analyse 3-D osteolytic lesions in mice with cancer-
induced bone disease. To this end, we have developed Osteolytica, an image analysis software method featuring
an easy to use, step-by-step interface tomeasure lytic bone lesions. Osteolytica utilises novel graphics card accel-
eration (parallel computing) and 3-D rendering to provide rapid reconstruction and analysis of osteolytic lesions.
To evaluate the use of Osteolytica we analysed tibial micro-CT datasets from murine models of cancer-induced
bone disease and compared the results to those obtained using a standard ImageJ analysis method. Firstly, to
assess inter-user variability we deployed four independent researchers to analyse tibial datasets from the
U266-NSG murine model of myeloma. Using ImageJ, inter-user variability between the bones was substantial
(±19.6%), in contrast to using Osteolytica, which demonstrated minimal variability (±0.5%). Secondly, tibial
datasets from U266-bearing NSG mice or BALB/c mice injected with the metastatic breast cancer cell line 4T1
were compared to tibial datasets from aged and sex-matched non-tumour control mice. Analyses by both
Osteolytica and ImageJ showed signiﬁcant increases in bone lesion area in tumour-bearing mice compared to
control mice. These results conﬁrm that Osteolytica performs as well as the current 2-D ImageJ osteolytic lesion
analysis method. However, Osteolytica is advantageous in that it analyses over the entirety of the bone volume
(as opposed to selected 2-D images), it is a more rapid method and it has less user variability.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).eed for Osteolytica. P.R. and T.K.
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A classical feature of malignancies such as multiple myeloma (MM)
and metastatic breast cancer (MBC) is a destructive bone disease
featuring the formation of focal osteolytic lesions [1,2]. In both cases,
formation is driven by increased osteoclastic bone resorption and re-
duced osteoblastic bone formation, speciﬁcally mediated by osteoclast
activating factors [3,4] and osteoblast inhibitory factors [5,6] secreted
by malignant cancer cells. Osteolytic lesions are considered a cardinal
sign of MM [7] and MBC [8], and assessment of them is of substantial
clinical importance.
A number of in vivo murine models of MM and MBC are in use
worldwide as a platform to study the biology of these diseases andthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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associated bone disease. For MM, these include the 5TMM murine
myeloma syngeneic series (5T2MM, 5T33MM and 5TGM1) [9–11]
and various immune deﬁcient xenograft models using NOD/SCID
[12,13], SCID-hu [14–16], SCID-beige [17], SCID-Rab [18–20] and
more recently NOD/SCID-γ mice [21–23]. There are also transgenic
models of MM, including mice that are genetically altered to over-
express MYC [24], Myc/B cell extra-large (BCl-XL) [25] and X-box
binding protein 1 (XBP-1) [26]. ForMBC, these include the 4T1murine
breast cancer syngeneic model [27] and the MDA-MB-231 xenograft
model [28]. As with the human diseases, all of these models demon-
strate the formation of osteolytic lesions as tumour load increases.
These lesions can vary considerably from a relatively low number
of large lesions to a higher number of smaller lesions. The analysis
of osteolytic lesions, usually recorded as a number or an area, is
used as a marker of disease progression and to assess the effects
of therapies designed to reduce bone disease. However, given the
complex 3-D structure of bone, capturing the full effects of thera-
peutic agents on bone disease is deceptively difﬁcult. Methods
used to analyse osteolytic lesions have included crude counts con-
ducted on poor quality 2-D plain radiographs [29] through to
more technologically advanced methods that utilise imaging software,
such as ImageJ (v. 1.47 t, NIH, USA) applied in various ways to ﬁrst
2-D X-rays [30] and later 3-D micro-CT reconstructions [31]. These
methods are time-consuming, inaccurate, and suffer from inter-user
variability that leads to poor reproducibility of results and possible
user bias.
To tackle these problems we have designed Osteolytica, a software
package for the analysis of cancer-induced osteolytic lesions featuring
an easy to use, step-by-step interface. It utilises novel graphics card ac-
celeration (parallel computing) of localised surface reconstruction tech-
niques and 3-D volume rendering to provide rapid reconstruction and
analysis of osteolytic lesions. In this report, we ﬁrstly assessed the
inter-user variability of results obtained using Osteolytica compared to
those obtainedwith ImageJ analysis. Secondly,we compared the results,
using both methods, from a xenograft model of myeloma study and a
murine metastatic breast cancer study.
2. Methods
2.1. Cell lines
U266 cells (derived from the peripheral blood of a 53-year-old man
withMM)were purchased from LGC Standards (UK). 4T1murine breast
cancer cells (originally derived from a spontaneous mammary tumour
in a BALB/c mouse [27]) were kindly donated by Prof. Janine Erler
(Biotech Research & Innovation Centre, University of Copenhagen,
Copenhagen, Denmark). Cell lines were genetically proﬁled by DSMZ
and ATCC using short tandem repeat analysis to conﬁrm their identity.
U266 cells were cultured in RPMI 1640 medium containing 10% foetal
calf serum (FCS), 100 U/ml penicillin and 100 μg/ml streptomycin. 4T1
cells were cultured in DMEM medium containing 10% FCS, 100 U/ml
penicillin and 100 μg/ml streptomycin. For both cell lines, all reagents
were from Gibco, Paisley, UK. Cells were cultured at 37 °C in 5% CO2
until required.
2.2. Mice
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice and BALB/c mice
were purchased from Charles River (Margate, UK).
2.3. Ethics statement
All procedures involving animals were approved by the Home
Ofﬁce (PPL 40/3462) and the University of Shefﬁeld's Animal Ethics
Committee.2.4. In vivo studies
2.4.1. U266-NSG myeloma model
8–9 week-old male NSG mice were divided into a non-tumour con-
trol group (n = 4) and a tumour group (n = 4). Mice in the control
group were injected intravenously (i.v.) with 100 μl PBS via the tail
vein. Mice in the tumour group were injected i.v. with 1 × 106 U266
cells. At the ﬁrst signs of morbidity, at 8 weeks post-tumour cell injec-
tion, all mice were sacriﬁced.
2.4.2. 4T1 breast cancer model
10 week-old female BALB/c mice were divided into a non-tumour
control group and a tumour group (n = 6/group). Mice in the control
group were injected with 100 μl PBS into the mammary fat pad. Mice
in the tumour groupwere injectedwith 1 × 105 4T1 cells into themam-
mary fat pad. All mice were sacriﬁced at 14 days post-tumour cell
injection.
For all studies, the right tibiae were dissected free of soft tissue and
ﬁxed in 10% neutral buffered formalin.
2.5. Micro-CT analysis
Tibiae were scanned on a Skyscan micro-CT scanner (1172a, Bruker,
Belgium) at 50 kV and 200 μA using a 0.5mmaluminiumﬁlter and a de-
tection pixel size of 4.3 μm. Images were captured every 0.7° through an
180° rotation with a 2× averaging of each bone. Scanned images were
reconstructed using Skyscan NRecon software (v. 1.6.9, Bruker,
Belgium) and datasets were resized using Skyscan CTAn (v. 1.14.4,
Bruker, Belgium).
2.6. ImageJ: 2-D analysis of osteolytic lesions
Trabecular bone was ﬁrstly removed from the datasets, leaving only
the cortical bone shell, using Skyscan CTAn. Datasetswere volumetrical-
ly rendered using Drishti (v. 1.0, ANU Vizlab, Australia), and then im-
aged. Tibiae were taken to be roughly triangular in cross-sectional
proﬁle, and so imageswere taken of these three different sides (the con-
cave face, the face adjacent to the back of the ﬁbular and the ﬂat face),
each time with the bone clipped in half so that any lesions showed
through to the background colour behind. Images were then analysed
using ImageJ (v. 1.47t, NIH, USA). Each image was binarised and
thresholded so that bone lesions appeared as areas of red. The surface
areas of these red regions were measured and the total surface area of
all the lesions as a proportion of the bone area was then calculated for
each bone.
2.7. Osteolytica: 3-D analysis of osteolytic lesions
A volumetric dataset from a micro-CT scanner was imported into
Osteolytica and the maximum diameter for a single bone lesion speci-
ﬁed. Maximum diameter was speciﬁed manually at 900 μm. The soft-
ware ﬁrst expanded the sample bone volume until there were no
holes on the outer surface. A contraction process was then performed
from the outside surface of the expanded volume, which continued
until the highest overlapping ratio between the contracted surface and
the original sampled bone volumewas found. This determined the opti-
mal reconstruction of the sampled bone volume. The addition of the
contracted volume to the original sampled bone volume formed the
ﬁnal bone reconstruction producing osteolytic lesion counts and area
measurements.
2.8. Statistical analysis
All data were assumed to be non-parametric and analysed using a
Mann–Whitney test. Signiﬁcance is indicated where p b 0.05 and all
data are expressed as mean ± SD.
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3.1. Osteolytica is a user-friendly interface that rapidly measures the
number and area of osteolytic lesions
Osteolytica was designed to be easier, faster and less biased than
previous lesion analysismethods such as themanual counting of lesions
evident on an X-ray (Fig. 1A) or ImageJ 2-D analysis (Fig. 1B).
Osteolytica was developed solely to count the number and area of
osteolytic lesions of a 3-D bone volume, thereby quantifying the full ex-
tent of any cancer-induced bone disease (Fig. 1C). It was not designed to
measure standard micro-CT parameters, such as trabecular volume and
spacing, and should therefore be seen as an addition to standard micro-
CT software and not a replacement. The datasets used in this publication
were obtained using a Skyscan micro-CT scanner, but datasets
from other micro-CT scanner, such as Scanco, and clinical CT scanners
would also be compatible.
The software features an easy to use, step-by-step interface preced-
ed by a ﬁle selection interface, which allows users to input a volumetric
sample and apply a binary threshold. The ﬁrst step of the analysis
process is for a user to provide a volume selection. The user loads the
desired dataset, speciﬁes the pixel resolution of that dataset and clicks
on it, and the software then deselects any disconnected volumetric
areas from the main area of interest, such as pieces of ﬂoating patella
(Fig. 1Di.). The second stage involves specifying a maximum lesion
diameter. The user can manually type in a diameter, or they can click
across the lesion on-screen and the software will automatically input
that diameter (Fig. 1Dii.). The ﬁnal stage provides analysis results
(output) of the sample volume by showing the lesion analysis measure-
ments (Fig. 1Diii.). Every lesion found is listed individually in order of
size, and below the total lesion area as a proportion of the bone is
displayed. During this ﬁnal stage individual osteolytic lesions can be re-
moved through 3-D picking or via de-selection from a list of lesions
sorted by lesion size, for example, to remove naturally occurring holes
such as those for blood vessels. In total, the user completes 3 steps
and the software carries out 4 separate processes (Fig. 1E). Other than
dataset resizing Osteolytica requires no other dataset preparation,
unlike the 2-D ImageJ method that calls for lengthy volumetric ren-
dering and image capture of the dataset prior to lesion analysis. In
total, using the 2-D ImageJ method requires 8 separate processes
(dataset resizing, trabecular hollowing, volume rendering, model
slicing, slice imaging, image cropping, image size standardising,
ImageJ analysis) and takes approximately 20 min per dataset.
Comparatively, using Osteolytica only requires 4 (dataset resizing,
Osteolytica dataset loading, Osteolytica maximum lesion size selecting,
Osteolytica lesion analysis) and takes approximately 5 min per dataset.
In our experience, using Osteolytica is therefore four times faster than
using the 2-D ImageJ method. The software can be found at the follow-
ing link: http://www.osteolytica.com and downloaded for a small fee,
the proceeds of which are used to cover developmental costs.
The method of calculating lesions within Osteolytica uses a process
of reconstructing the surface of a volumetric sample (ﬁlling lesions)
and then subtracting the original surface from the reconstructed one
(Fig. 1C). Reconstruction is implemented through a novel two-stage
process of volumetric diffusion [32].Within the ﬁrst stage of this process
the volumetric surface is diffused outwards (according to the user spec-
iﬁed maximum lesion diameter) (Fig. 1Ci. and ii.). This expanded vol-
ume is then diffused inwards by a variable amount over the surface
(Fig. 1Ciii.). The variable inwards diffusion is optimised to ﬁnd the
highest overlapping ratio between the contracted surface and the orig-
inal sampled bone volume over a ﬁxed local area (based on the maxi-
mum lesion diameter). This has been found to provide the best
localised surface reconstruction. As the volumetric diffusion process is
computationally expensive this aspect of the software has been acceler-
ated through the use of parallel processing using the graphics process-
ing unit [33].3.2. Osteolytica has much lower inter-user variability and therefore much
better reproducibility compared to ImageJ
To assess the inter-user variability of Osteolytica compared to a 2-D
ImageJ analysismethod, 4 independent researchers analysed the same 5
datasets of micro-CT bone images using both methods. For both
methods, analysis of bone destruction was measured as total lesion
area as a proportion of the region of interest. For the 2-D ImageJmethod,
this meant percentage of the bone area imaged. For the 3-D Osteolytica
method, this meant percentage of the total bone area. This parameter
was chosen as it was felt that total lesion area gave a truer reﬂection
of the extent of bone destruction as opposed to simple numbers of
osteolytic lesions. These datasets were tibiae from NSG mice injected
with U266 myeloma cells and sacriﬁced at the end stage of disease.
Osteolytic lesions could be visualised in all of the bones (Fig. 2A).
Using the ImageJ analysis method (Fig. 2Bi.), when collated inter-user
variability for dataset 1 was 18.4%, for dataset 2 was 10.3%, for dataset
3 was 17.4%, for dataset 4 was 30.6%, and for dataset 5 was 21.2%.
Thus, the average inter-user variability was found to be 19.6%. In con-
trast, analysis using Osteolytica (Fig. 2Bii.) resulted in 0.1% variability
for dataset 1, 0.76% for dataset 2, 0.13% for dataset 3, 0.89% for dataset
4 and 0.74% for dataset 5. Average inter-user variability using
Osteolytica was 0.53%, which was substantially lower than when using
the 2-D ImageJ method.
3.3. Osteolytica and ImageJ are both able to detect signiﬁcant differences in
myeloma-induced osteolytic lesions
To compare Osteolytica lesion analysis to ImageJ analysis, datasets
from NSG mice injected with the U266 cells were assessed and com-
pared to non-tumour controls (Fig. 3A). For both methods, analysis of
bone destruction was measured as total lesion area as a proportion of
the region of interest. The tumour group had a signiﬁcantly larger total
lesion percentage compared to the non-tumour group when using
both the ImageJ 2-D method (Fig. 3Ai.) and Osteolytica (Fig. 3Aii.).
Using ImageJ (Fig. 3Aiii.), there was a signiﬁcant difference of p b 0.05
between the tumour group and the naïve group (0.56 ± 0.36% vs
0.070 ± 0.058%). Similarly using Osteolytica (Fig. 3Aiv.), there was a
signiﬁcant difference of p b 0.05 for the tumour group versus the non-
tumour group (6.9 ± 1.9% vs 3.7 ± 0.5%).
3.4. Osteolytica can be used to assess osteolytic lesions in a breast cancer
murine model
Next, we assessed the use of Osteolytica compared to the 2-D ImageJ
method in a different murine model of cancer-induced bone disease.
Tibial micro-CT datasets from BALB/c mice injected with 4T1 breast
cancer cells were assessed compared to non-tumour mice (Fig. 3B).
For both methods, analysis of bone destruction was measured as total
lesion area as a proportion of the region of interest. The tumour group
had a signiﬁcantly larger total lesion percentage compared to the non-
tumour group when using both analysis methods (Fig. 3B). Using
ImageJ (Fig. 3Biii.), there was a signiﬁcant difference of p b 0.01 for
the tumour group versus the non-tumour group (1.25 ± 0.36% vs
0.089 ± 0.064%). Similarly using Osteolytica (Fig. 3Biv.), there was a
signiﬁcant difference of p b 0.01 between the tumour group and the
non-tumour group (4.6 ± 1.0% vs 2.8 ± 0.4%).
4. Discussion
Cancer-induced bone destruction leading to severe pain, immobility
and disﬁgurement is one of themost devastating aspects of the patient's
experience of cancer [1]. New treatments to prevent osteolytic bone dis-
ease and to eliminate cancer from the bonemarrowmicroenvironment
are urgently needed. Current therapy relies almost exclusively on
bisphosphonates, which have been proved to reduce the skeletal
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Fig. 2.Osteolytica reduces inter-user variability compared to a 2-D ImageJ analysismethod. (A) Representative micro-CT full-face images of tibia (n= 5), frommice injectedwith 1 × 106
U266 cells at the end stage of disease, used to assess inter-user variance. (B) Bone lesion area showing inter-user variance when using the 2-D ImageJmethod (19.6%) (i.) andwhen using
Osteolytica (0.53%) (ii.).
13H.R. Evans et al. / Bone 83 (2016) 9–16complications of malignancy [34–38] but do not lead to repair of
existing lesions.
To assess new and existing therapies in the treatment of cancer-
induced bone disease both immune-competent syngeneic and human
xenograft in vivomurinemodels are used. Some of thesemodels exhibit
severe osteolytic phenotypes including distinct lesions. These models
have provided important evidence concerning the efﬁcacy of both
anti-resorptive agents such as the bisphosphonate, zoledronic acid
[29,39], proteasome inhibitors such as bortezomib [40], osteoprotegrin
mimetics [19] and anabolic agents such as anti-Dkk-1 [30] (Novartis),
and the decoy activin receptor, RAP-011 (Acceleron) [41]. However, in
order to robustly assess these new reagents it is imperative that
osteolytic lesions are measured accurately and without bias. It has be-
come apparent that methods used to analyse the number and area of
osteolytic lesions are sub-optimal, especially with respect to inter-user
variability, reproducibility and consequent accuracy.
Here we have demonstrated a new software method, known as
Osteolytica, and compared it to an existing method using 2-D ImageJ
analysis, to measure osteolytic lesions from murine micro-CT datasets.
Osteolytica features a user-friendly, step-by-step digital interface,
which is easily mastered and quick to use. It allows complete 360° anal-
ysis of the bone's surface, unlike the 2-D ImageJmethod that only allows
for partial bone analysis, the results of which could skewanalysis. This is
illustrated in the murine study examining the inter-user variability be-
tween the two analysis methods (Fig. 2). In this study, the full-face im-
ages of the tibiae (Fig. 2A) appear to show that Dataset 4 has the least
osteolytic disease, and this is reﬂected in the ImageJ method results. It
is only when using Osteolytica, and thus considering the entirety of
the bone, that it becomes apparent that Dataset 1 is actually the least
osteolytic.Fig. 1.Osteolytica is a user-friendly interface that rapidlymeasures the number and area of osteo
lesion counts. (B) Micro-CT 2-D reconstruction of a mouse tibiae showing the 3 aspects used a
Osteolytica, showing (i.) volume selection, (ii.) volume expansion and (iii.) detection andmeasu
showing (i.) volume selection, where the user loads the dataset and selects the volume of inte
ameter speciﬁcation, where the user either manually enters the diameter or draws it on the scr
sured, as well as total lesion area and total lesion proportion of the volume. Lesions can be des
intermediate computer processes.The software details and tags each individual lesion, aswell as calcu-
lating total bone destruction present, and this can be displayed both as a
surface area and as a proportion of the total bone area. This tagging
feature does allow the user to remove naturally occurring holes such
as blood vessels if they wish — for example, most mice tibiae have a
blood vessel on the curved surface opposite to the back of the ﬁbula. Re-
moval of blood vessels, therefore, does require the user to have a certain
level of expertise. It is inadvisable in many cases, as cancer-induced
bone disease can widen already naturally occurring holes. It can also
be difﬁcult to pin-point the bone vessel hole in a heavily diseased
bone that it full of lesions. Finally, as Osteolytica is fully automated
there is much less scope for user bias from analysis of data. We have
shown that repeated analysis of the same dataset by different users
yields the same result, whereas results differ markedly when using
the existing method using 2-D ImageJ analysis.
Comparing the results obtained from the two murine studies, it ap-
pears that the 2-D ImageJ method actually produces better results
than when using Osteolytica. However, this would be a misinterpreta-
tion, because obtaining a good result from a technique does not neces-
sarily mean that that technique is correct. As we have mentioned
above, using the ImageJ method only offers a partial analysis of the
bone using three 2-D images. 2-D images of a 3-D structure can ﬂatten
and distort its features, particularly curved surfaces, leading to inaccu-
rate measurements. Finally, the amount of volume manipulation and
bone imaging required increases the chance for user error and decreases
the likelihood of reproducibility. Therefore, wewould argue that though
the results gained by using Osteolytica may not look as impressive as
those produced fromothermethods on the surface, they are almost cer-
tainly more accurate. Currently, there is no established way of knowing
the true value of a bone's osteolytic disease. Micro-CT allows accuratelytic lesions. (A) Plain radiograph of amouse tibia used as the original template formanual
s templates for 2-D ImageJ analysis to assess lesion area and number. (C) The 3 stages of
rement of lesions. (D) Representative screenshots of the 3 steps of theOsteolytica software
rest, and the software removes any unattached ﬂoating volumes (ii.) maximum lesion di-
een and (iii.) lesion analysis results, where the software lists the area of every lesion mea-
elected at this stage if required. (E) Flow diagram showing the 3 steps of Osteolytica and
Fig. 3. Osteolytica is able to detect signiﬁcant differences in osteolytic lesion area in
micro-CT scans from murine models of cancer-induced bone disease. (A) Representative
images of tibiae from mice injected with 100 μl PBS (Naïve, n = 4) (i.) or 1 × 106 U266
cells (n = 4) (ii.). Bone lesion area when using the 2-D ImageJ method (0.56 ± 0.36% vs
0.07 ± 0.058%) (iii.) and when using Osteolytica (6.9 ± 1.9% vs 3.7 ± 0.5%) (iv.).
(B) Representative images of tibiae from mice injected with 100 μl PBS (Naïve, n = 6)
(i.) or 1 × 104 4T1 cells (n = 6) (ii.). Bone lesion area when using the ImageJ method
(1.25 ± 0.36% vs 0.089 ± 0.064%) (iii.) and when using Osteolytica (4.6 ± 1.0% vs
2.8 ± 0.4%) (iv.). Data are expressed as mean ± SD and signiﬁcance from the control
group is indicated, where *p b 0.05 and **p b 0.01.
14 H.R. Evans et al. / Bone 83 (2016) 9–16and complete visualisation of bone lesions but its supporting com-
puter software offers no method of capturing this information,
hence the reason why we designed Osteolytica. Therefore, although
it is difﬁcult for us to test the accuracy of Osteolytica we are conﬁdent
that for the reasons discussed, Osteolytica gives the most accurate
analysis of bone destruction currently possible.Presently, there is only one published methodology for the analysis
of bone destruction in 3-D, which uses a novel algorithm to ‘unwrap’
the cortical bone and produce a ﬂat, 2-D image that can be analysed to
measure lesion number and area. This method of analysis is a marked
improvement from the 2-D ImageJ method, the problems of which we
have detailed above. However, this unwrappingmethod still has its lim-
itations, andwe believe that Osteolytica demonstrates an improvement
on this 3-D method. The unwrapping method is only applied to the cy-
lindrical portion of the bone below the growthplate,most likely because
the unwrapping algorithm cannot deal with the more complex, curved
surface of the growthplate and the epiphysis above it. Thus, a large por-
tion of the bone is excluded, and this is made more problematic by the
fact that many models of osteolytic disease develop lesions primarily
in that growthplate region, due to the cortical wall being much thinner
and more porous. A large proportion of disease would therefore avoid
detection. Osteolytica can cope with the complexities of the shape of
the bone in its entirety through the use of its two-stage volumetric dif-
fusion method, so no region of the bone is ignored and no data is lost.
Osteolytica is, however, designed primarily to analyse the cortical
bone of long bones. It can analyse lesions in ﬂat bones, such as the
calvaria, but it has not been optimised for complex structures that con-
tain very acute angles, as the software will take those angles to be le-
sions. It would therefore not be appropriate to use Osteolytica to
analyse lesions in vertebrae or in trabecular bone. Very large datasets
would also require some resizing and pixel smoothing, which may
lead to the loss of very small holes.
The successful deployment of Osteolytica in the detection and mea-
surement of osteolytic lesions in in vivomodels of cancer-induced bone
destruction paves theway for its deployment as an additional diagnostic
modality in patientswith cancer-induced bone disease. The detection of
cancer induced bone disease in patients remains a crucial issue. In the
case of myeloma, detection of bone disease is a critical aspect of diagno-
sis, being a key determinant of whether to commence chemotherapy
[42]. The optimum radiological method of assessing bone destruction
in myeloma is currently the subject of substantial international debate
[43]. Plain radiography remains the screening modality of choice in
the detection of osteolytic lesions, given that it is universally available
and inexpensive [44]. CT, magnetic resonance imaging (MRI) and posi-
tron emission tomography–computerised tomography (PET/CT) are
frequently used to clarify ambiguous lesions on X-ray or anatomical
sites of unexplained pain or suspected malignant inﬁltration [43].
As shown, Osteolytica is able to detect and analyse bone lesions
from murine micro-CT datasets. We anticipate that the application of
Osteolytica to human CT datasets would be entirely feasible once
conditions are optimised. Datasets would need to be high-deﬁnition
scans, i.e. of sufﬁciently small pixel resolution to allow identiﬁcation of
lesions, and to contain a sufﬁcient number of image slices in order to
produce a smoothly deﬁned 3-D model. Generally speaking, there
should be a 4:1 ratio between the object of interest and the minimum
pixel resolution, so to detect a lesion of 20 μm diameter the pixel reso-
lution should be at least 5 μm. Because of the resultant ﬁle size from
these optimisations, the datasets would probably require a degree of
resizing and pixel smoothing. Once these conditions were met, howev-
er, Osteolyticawould provide a novel and powerfulmethod of detecting
and quantifying cancer-induced bone destruction. Furthermore, serial
measurements using Osteolytica would enable the detection of new or
progressive disease, and could also monitor response to bone targeted
treatments including repair of existing lesions driven by the application
of bone anabolic agents. We are currently seeking ethical approval to
apply Osteolytica to human CT datasets.
In summary, Osteolytica software is quick and easy to use. It per-
forms as well as the current 2-D ImageJ method of analysing osteolytic
lesions, but also substantially reduces inter-user variability. Osteolytica,
therefore, has the potential to become the international standard
method of analysis in the in vivo research context. In addition,
Osteolytica has a potentially important clinical role as a better detection
15H.R. Evans et al. / Bone 83 (2016) 9–16method of bone disease. This has important implications for treatment
decisions, including when to commence chemotherapy and when to
call for orthopaedic intervention.
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